Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment
Viruses · 2024
DOI: 10.3390/v16081277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Lindsey R Riback und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA. Hauptthemen laut MEDLINE: Hepatitis C, Substance Abuse, Intravenous, Risk-Taking. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute on Drug Abuse, National Institutes of Health, NIMHD NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
Polysubstance use (PSU), injection drug use (IDU), and equipment sharing are associated with bloodborne infection (BBI) transmission risk, particularly Hepatitis C Virus (HCV), yet data on PSU in low- and middle-income countries (LMICs) is limited. We report on baseline PSU, medication-assisted treatment (MAT) engagement, and motivation to reduce IDU among 95 people who inject drugs (PWID) who accessed needle and syringe programs (NSP) in Nairobi and Coastal Kenya prior to HCV treatment. Bivariate and multivariate logistic regression were used to examine the associations between PSU and behaviors that confer HCV transmission and acquisition risks. Most participants (70.5%) reported PSU in the last 30 days, and one-third (35.8%) reported PSU exclusive to just heroin and cannabis use. Common combinations were heroin and cannabis (49.3%), and heroin, cannabis, and bugizi (flunitrazepam) (29.9%). Participants at baseline were receiving MAT (69.5%), already stopped or reduced IDU (30.5%), and were HIV-positive (40%). PSU was significantly associated with IDU (p = 0.008) and the number of times (p = 0.016) and days (p = 0.007) injected in the last 30 days. Participants reported high PSU and equipment sharing, despite high MAT engagement. While co-locating BBI treatment within existing harm reduction services is necessary to promote uptake and curb re-infection, tailored services may be needed to address PSU, particularly in LMICs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA.
- Kenya Ministry of Health, National AIDS&STI Control Program (NASCOP), 19361 Nairobi, Kenya.
- Yale School of Nursing, Yale University, Orange, CT 06477, USA.
- New York Academy of Medicine, New York, NY 10029, USA.
ORCID-Profile: Lindsey R Riback
Förderung
- National Institute on Drug Abuse, National Institutes of Health
- NIMHD NIH HHS
- NIDA NIH HHS
- National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH)
- Albert Einstein Global Health Center
- JCOIN cooperative
- NIDA
- National Institute on Minority Health and Health Disparities (NIMHD)
Zitieren
APA
Riback, L. R., Nyakowa, M., Lizcano, J. A., Zhang, C., Cherutich, P., Kurth, A. E., & Akiyama, M. J. (2024). Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment. Viruses. https://doi.org/10.3390/v16081277
Vancouver
Riback LR, Nyakowa M, Lizcano JA, Zhang C, Cherutich P, Kurth AE, et al. Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment. Viruses. 2024. doi:10.3390/v16081277
BibTeX
@article{Riback2024,
author = {Riback, Lindsey R and Nyakowa, Mercy and Lizcano, John A and Zhang, Chenshu and Cherutich, Peter and Kurth, Ann E and Akiyama, Matthew J},
title = {Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16081277}
}
EUVIMED